 Home > Biochemistry News > Biotechnology News > Bayer's innovative combination therapy submits application for additional indications in Japan

Bayer's innovative combination therapy submits application for additional indications in Japan

 Last Update: 2022-04-29
 Source: Internet
 Author: User

Tags

plica fimbriata cancer

cozaar 50 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Bayer has announced that it has submitted an additional indication application for the oral androgen receptor inhibitor (ARi) darolutamide to the Japanese Ministry of Health, Labour and Welfare (MHLW), seeking approval for darolutamide in combination with Docetaxel and androgen deprivation therapy (ADT) in patients with prostate cancer with distant metastases

Prostate cancer is the second most commonly diagnosed malignancy in men worldwide

Dalotamide has a unique chemical structure and can bind to androgen receptor with high affinity, showing strong antagonistic activity, thereby inhibiting receptor function and growth of prostate cancer cells

This application submission is based on positive results from a pivotal Phase 3 clinical trial and has been published in the New England Journal of Medicine

In addition, the trial met a number of secondary endpoints, including delaying the conversion of patients to castration-resistant prostate cancer and delaying the onset of pain progression

▲The overall survival data of this phase 3 clinical trial (Image source: Reference [2])

References:

[1] Bayer submits application for additional indication of Nubeqa™ (darolutamide) in Japan.

[2] Smith et al.

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.